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Pretrea tm ent with a low dose of recombinant hum an interleukin-1 p (IL-1) (3 to 30 |xg/kg) 24 h before a 
lethal Pseudomonas aeruginosa infection prolongs survival in neutropenic mice. We investigated the role of the 
type 1 IL-1 receptor (IL-1RI) and 1L-1R1I in this IL-l-induced protection by using a specific IL-1 receptor 
antagonist  (1L-1-Ra), which blocks effects mainly via 1L-1RI. Pre trea tm ent with IL-IRa before IL-1 partially 
blocked the IL-l-induced enhanced survival, whereas p re trea tm ent with a specific neutralizing monoclonal 
antibody to IL-1RI (35F5) eliminated the IL-1 induced protection. The nonapeptide fragment 163-171 of 
recombinant hum an IL-l[i, which possesses the imniunoadjuvant but not the inflammatory effect of the entire 
molecule via a non-receptor-mediated signal transduction process, did not reproduce the IL-l-induced pro­
tection. IL-1-induced protection was associated with reduced serum aspar ta te  am inotransferase  and alanine 
am inotransferase  concentrations in conjunction with ameliorated histopathology of the liver. These findings 
may be due to reduced cytokine production and cytokine sensitivity of target cells after infection. We conclude 
that the IL-l-induced nonspecific resistance to infection is mediated by cells bearing IL-1R1 and is associated 
with a reduction of liver damage.
Administration of the proinflammatory cytokine interleu­
kin-1 (IL-1) leads to enhanced nonspecific resistance to gram- 
positive and gram-negative bacteria, fungi, and plasmodia (27). 
For example, we have shown that pretreatm ent with a single 
low dose (3 to 30 |xg/kg) of recombinant human IL-1 (3 (rhIL-lp) 
24 h before a lethal gram-negative infectious challenge with 
Klebsiella pneumoniae or Pseudomonas aeruginosa enhances the 
survival of normal and neutropenic mice, respectively (19, 20). 
The mechanism of this protection has been only partially clar­
ified. A direct antimicrobial effect of IL-1 has been excluded in 
vitro (19), and whether IL-1 induces enhanced clearance of 
microorganisms in vivo is controversial (27). The protective 
effect of IL-1 against infectious challenges in granulocytopenic 
mice indicates that neutrophils do not play a major role (19,
27). Glucocorticosteroids, eicosanoids, or cytokines such as 
IL-6, IL-8 , and granulocyte-macrophage colony-stimulating
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factor are not likelv to mediate the IL-l-induced resistance toJ
infection (22-24, 26). However, IL-l-induced tumor necrosis 
factor alpha and IL-l-induced acute-phase proteins play some 
role as mediators of the IL-1 effect (22. 23).
Two receptors for IL - 1 . which difl'er in both size and tissue 
distribution, have been fully characterized (11, 16). The type I 
IL-1 receptor (IL-1RI) is an 80-kDa protein present on '1' 
lymphocytes, endothelial cells, fibroblasts, and hepatocytes, 
and IL-1RII is a 68-kDa protein found on B lymphocytes, 
monocytes, and neutrophils (5). In the present study, we have 
investigated the roles of IL-1RI and IL-IRII in the IL-1 [3- 
induced protection against infection in mice by using neutral­
izing monoclonal antibodies to murine IL-1 RI and IL-1 R 1 1 , 
respectively (5, 7). We also used the IL-1 receptor antagonist 
(IL-1 Ra), a naturally occurring 25-kDa glycoprotein belonging 
to the IL-1 gene family, which blocks IL-1 effects by specifically
binding mainly to IL-1 RI without agonist activity ( 1 ). To fur­
ther elucidate the role of IL-1 receptors, we investigated 
whether the immunostimulatory 163-171 nonapeptide frag­
ment of  human IL-1 [3. which acts via a non-receptor-mediated 
signal transduction pathway (3, 4), exerts protective activity.
Recently, we demonstrated that the IL-l-induced protection 
against infection is associated with reduced concentrations of 
tumor necrosis factor alpha and IL-6 in plasma during infec­
tion together with an increased level of m R N A  for the anti­
inflammatory IL-IRa (25). In the present study, we have also 
investigated whether this IL-l-induced modulation of cytokine
J
responses is reflected in a decrease in liver damage.
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MATERIALS AND M ETHODS
Mice. Female outbred Swiss mice (weight. 21) to 25 g; T N O . Rijswijk. The  
Netherlands) were kept under specific-pathogcn-frec conditions. Standard irra­
diated lab chow (RMII-TM: Hope Farms, Woerden, The Netherlands) and 
acidified water were available ad libitum.
Materials. rhIL-lfi was generously provided by P. Graber (Glaxo. Geneva.  
Switzerland). Human IL-1 Ra ( I ) was donated bv J. Vannice, Svnereen. Boulder.
9  9
Colo. Inactivated rh lL -ip  and IL-IRa (control treatments) were prepared by 
heating rhIL-lfi and IL-IRa at 95°C for 30 min. For in vivo administration. 
rhIL-ip. IL-IRa. and the control proteins were dissolved in pyrogen-lree phos­
phate-buffered saline (pH 7.4) with 2 %  (vol/vol) mouse serum.
35F5, a rat immunoglobulin G l  (IgG I)  anti-mouse IL-IRI monoclonal anti­
body (5), was a kind nill from R. Chizzonite. Hollmann-La Roche. Nutley, N.J. 
As a control antibody, a purified rat IgG (I-4I3I)  was obtained Irom Sigma 
Immunochemicals (St. Louis. Mo.). ALVA-42, a murine IgGI monoclonal an­
tibody blocking the murine IL-IRII (7). and the IL-1(3 peptide I(>3-I7I (4) were  
donated by P. Ghiara (Sclavo. Siena. Italy). Purified mouse IgG (1-5381). used as 
control antibody for ALVA-42, was obtained from Sigma.
Survival experiments. Since P. aeruginosa (A TC C  27853) does not kill normal 
mice, mice were rendered neutropenic (< 0 .5  X It)1' granulocytes per liter) by two 
subcutaneous injections o f  cyclophosphamide (A ST A  Pharma, Frankfurt. G er­
many) on days 4 and I before challenge (150 and 100 mg/kg. respectively). On 
day I before challenge, SOI) ng of  human IL-lfi or control treatment was injected 
intraperitoneally (i.p.) in 0.1 ml; 24 h later (lime zero), a lethal challenge with 0.5 
x 10 to 1 x 10 C F U  of  P. aeruginosa was uiven intramuscularly in the left tliiuh 
muscle. Six hours after the infection, gentamicin (120 mg/kg; Schering, Ken- 
ilwoth, N.J.) was administered subcutaneously in order to postpone the lime of  
death and thus accentuate the differences between treatment groups. Mortality 
was recorded for at least 48 h.
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FIG. 1. Survival o f  neutropenic mice infected intramuscularly with P. aerugi­
nosa (time zero) after various pretreatments. (A )  Mice were pretreated at 24.25 
h before infection with 800 ng o f  IL-IRa or inactivated IL-IRa (control treat­
ment [C]) i.p. and at 24 h before infection with 800 ng of  rhIL-l|3 or inactivated 
IL-l(i (control treatment) i.p. Mice pretreated with inactivated IL-IRa and 800 
ng of  IL-1 were protected significantly in comparison to mice receiving control 
injections on both occasions ( \ 2 =  9.79; P  <  0.005), whereas mice pretreated 
with 800 ng o f  IL-IRa followed by 800 ng o f  IL-1 were protected to a nonsig­
nificant extent. The difference between IL-1-treated mice pretreated with IL-1 Ra 
and those pretreated with inactivated IL-IRa was not significant. Also, the 
difference between mice receiving either IL-IRa or inactivated IL-IRa followed  
bv inactivated IL-1 was not significant (22 mice per group). (B) Mice were 
pretreated i.p. at 42 h before infection with 200 |xg o f  the neutralizing anti-IL- 
IRI antibody 35F5 or control IgG and at 24 h before infection with 800 ng o f  
rhlL -ip  or inactivated rhIL-l(3 (control treatment) i.p. Mice receiving control 
IgG followed by IL-1 were protected significantly in comparison to mice receiv­
ing control IgG followed by inactivated IL-1 ( \ : =  6.13; P  <  0.025). The survival 
o f  IL-l-treated mice pretreated with 35F5 was not significantly different from 
that o f  control treated mice pretreated with 35F5. Also, the difference between
Liver enzymes. For assessment o f  the effect o f  IL-1 on liver enzymes, aspartate 
aminotransferase (A S A T ) levels and alanine aminotransferase (A L A T ) levels in 
nonhemolytic EDTA-plasma from IL-1-pretreated and control neutropenic mice 
were measured 24 h after intramuscular P. aeruginosa infection. A S A T  and 
A L A T  levels were assessed by routine procedures (BM/Hitachi 747: Boehringer  
Mannheim, Mannheim. Germany).
Statistical analysis. Survival data were analyzed by use of  the log rank test 
(14). Comparisons of  biochemical and histopathologic data between treatment 
groups were made by the Kruskal-Wallis test. P  values o f  less than 0.05 were  
considered significant.
RESULTS
Effect of IL-IRa and IL-1RI and IL-IRII antibodies on IL- 
1-induced protection against infection. To investigate the in­
volvement of IL-1RI and IL-IRII in the IL-l-induced en ­
hanced resistance to infection, IL-IRa, which inhibits IL-1 
effects mainly via IL-1RI (10), was administered in a 100 to 
1,000-fold molar excess over IL-1. Doses of IL -IR a varying 
from 40 to 250 |xg administered i.p. 15 min before 800 ng of 
IL-1 i.p., analogous to the regimen found to be effective by 
others (10), did not significantly reduce the IL-l-induced pro­
tection of neutropenic mice against a lethal P. aeruginosa chal­
lenge (not shown). After 800 [jig of IL-1 Ra, a 1,000-fold molar 
excess over IL-1, there was a trend to reduction of the IL-l- 
induced protection, although the difference between the IL-l- 
treated group given a control pre treatm ent and that given 
IL-IRa pretreatm ent did not reach significance (Fig. 1A). 
These results suggest a potential role for IL-1RI in the IL-l- 
induced protection against infection. IL-IRa, however, is not 
completely specific for IL-1 RI, since it also binds to the murine 
IL-IRII, albeit with a much lower affinity (10, 11). Therefore, 
complete inhibition of the IL-1 effect by using even higher 
doses of IL -IRa would not allow one to distinguish between a 
complete effect via IL-1 RI due to more effective blockade and 
an additional IL-1 effect via IL-IRII.
In an alternative approach to establish the possible role of 
IL-1RI or IL-IRII, we performed experiments with 35F5, a 
specific neutralizing rat anti-murine IL-1RI monoclonal anti­
body (5), and ALVA-42, a monoclonal antibody directed 
against the murine IL-IRII (2, 7).
Pretreatment with 35F5 (200 |i.g i.p.), 4 h before IL-1. was 
almost fully effective, reducing significantly the IL-l-induced 
enhanced survival (x2 =  5.92; P <  0.025) to nonsignificant 
protection (x2 =  2.53; P =  0.12) (12 mice per group) (data not 
shown). When the same i.p. dose of 35F5 was administered 18 
h before IL-1, it abrogated the IL-l-induced protection, cor­
roborating the data obtained with IL-IRa (Fig. IB). Survival 
after pre trea tm ent of control-treated infected mice with 200 
(jig of either rat IgG or 35F5 did not differ significantly from 
survival after p re trea tm ent with saline, and therefore only re ­
sults for the saline-pretreated group are presented in Fig. IB.
When pre trea tm ent with either 35F5 or ALVA-42 was per­
formed within one experiment, the complete inhibition of the 
IL-1 effect by 200 fig of 35F5 administered 18 h before IL-1
mice receiving either control IgG or 35F5 followed by inactivated IL-1 was not 
significant (20 mice per group). (C) Mice were pretreated i.p. at 42 h before  
infection with 200 M-g of  35F5, A LV A -42, or control IgG and at 24 h before  
infection with 800 ng of  rhIL-ip or inactivated rhIL-l|3 (control treatment) i.p. 
Mice receiving IgG followed by IL-1 were protected significantly in comparison  
to mice receiving IgG followed by inactivated IL-1 ( \ 2 =  6.63; P  =  0.01). Mice 
receiving A L V A -42 followed by IL-1 were protected significantly in comparison  
to mice receiving A L V A -42  followed by inactivated IL-1 ( \ 2 =  3.86; P  =  0.05). 
The difference in survival between IL-1-treated mice pretreated with A LV A -42  
and those pretreated with control IgG was not significant. The survival o f  IL-l-  
treated mice pretreated with 35F5 did not differ significantly from that o f  mice 
pretreated with inactivated IL-1 and pretreated with either 35F5 or control IgG 
(10 or 11 mice per group).
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was conlirmed. whereas no effect was observed with 200 jj.g of 
ALVA-42, a dose reported to be effective in reduction of 
lipopolysaccharide lethality (2, 7) (Fig. 1C). The survival of 
mice that received heat-inactivated IL-1 and pretreatm ent with 
either rat IgG. 35F5, or ALVA-42 did not differ from that of 
mice treated with inactivated IL-1 and pretreated with murine 
IgG: therefore, in Fig. 1C only results for the latter group are 
shown. Since the survival of IL-l-treated mice pretreated with 
rat IgG did not differ significantly from that of mice pretreated 
with murine IgG. only results for the latter group are pre­
sented.
Effect of 163-171 peptide pretreatment on survival after 
infection. Next, we investigated the effect of the nonapeptide 
fragment (163-171) of human IL-Ip , which lacks a series of the 
inflammatory and acute-phase effects of the entire molecule 
but possesses a ranee of immunostimulating effects via non-
IL-1 R-mediatcd pathways (3, 4).
Whereas significant protection was produced by i.p. injec­
tion of S00 ng of IL.-l into neutropenic mice 24 h before a 
lethal P. aeruginosa infection, i.p. pre treatm ent with nonapep­
tide doses varying from 1 to 320 |xg (a 21- to 6,800-fold molar 
excess over IL-1). which have been found to be effective by 
others (3, IS), did not enhance survival (not shown). Combined
i.p. administration of the same doses of the nonapeptide and 
800 ng of IL-1 did not affect the IL-1-induced protection 
against infection (not shown).
Effect of IL-1 pre treatm ent on liver enzymes after infection. 
For assessment of liver injury in infected mice, ASAT and 
ALAT levels in blood obtained from IL-1-pretreated and con­
trol-treated neutropenic mice were determined 24 h after a 
lethal intramuscular P. aeruginosa challenge, a time point at 
which no mice had yet succumbed. A LA T concentrations were
m
significantly reduced in the IL-1-pretreated group compared 
with the control group (101 and 367 U/liter, respectively; P = 
0.0095), whereas ASAT concentrations were not significantly 
reduced (819 and 1.340 U/liter. respectively) (seven to nine 
mice per group).
DISCUSSION
In this study, we found that IL-1 RI and not IL-IRII medi­
ates the protective effect of rh IL - lp  in lethal P. aeruginosa 
infection in neutropenic mice.
The role of IL-1RI was first investigated by using IL-IRa, a
C  •  W
competitive inhibitor of IL-1 a  and IL - lp  binding mainly to 
IL-1RI ( I ). A 1,000-fold molar excess of IL -IR a over IL-I 
partially blocked the IL-l-induced protection. Since high doses 
of IL-1 Ra may also block IL-1 effects via IL-IRII (1, 1(7), which 
has much less affinity for IL-1 Ra, studies with higher doses of
« r
IL-1 Ra would not differentiate between a more effective block­
ade of IL-1 effects via IL-IRI or a partial effect of IL-1 via 
IL-IRII.  Therefore, we used 35F5. a specific neutralizing an ­
tibody directed against the murine IL-IRI (5). Pretreatment 
with 35F5 eliminated the IL-l-induced protection against in­
fection, suggesting that this IL-1 effect is mediated via cells 
bearing IL-IRI. The complete lack of reduction of the IL-l- 
induced enhanced survival by pretreatment with ALVA-42, 
which is reported to block IL-1 RII (2, 7). underscores the role 
of IL-IRI. However, a recent report (6) suggests that this 
antibody does not bind to IL-IRII. which may be another 
explanation of the lack of effect. Neta et al. (12) also found that 
radioprotection induced by IL-1 pretreatment could be 
blocked by the 35F5 antibody, suggesting that IL-IRI was 
mediating this response. The key role of IL-IRI is corrobo­
rated by the recent paper of Sims et al. (17) reporting that the 
IL-l-induced signal transduction is mediated exclusively via
this receptor. Which type of IL-1 Rl-bearing cells play a role in 
the IL-l-induced protection remains to be clarified. O ur pre­
vious report (22) on a role of acute-phase proteins, produced 
by hepatocytes, which bear IL-IRI (10), is in accordance with 
the findings of this study. The same holds for induction bv IL-1 
of tumor necrosis factor alpha, which may be produced by 
endothelial cells, by fibroblasts, and bv monocytes via small
m i 7  J  • /
quantities of IL-IRI (17), and which has been shown in our 
protection studies to play some role (23). It is of interest that 
neither IL-IRa nor 35F5 alone was able to affect survival, as 
has been found in other studies (10). However, this may largely 
be explained by the single administration and the short half- 
lives of these reagents.
The IL-l-induced enhanced survival after infection could 
not be mimicked by the nonapeptide fragment (161-173) of 
rh IL -1 p. This immunostimulatory domain of rhIL-l(3 lacks 
inflammatory' effects such as pvrogenicity and induction of 
prostaglandins, IL-6, glucocorticosteroids, and acute-phase 
proteins (4). Boraschi et al. recently reported that the non­
apeptide enters the cell through a receptor-independent mech­
anism. possibly by passive diffusion through the cell membrane 
(3). This would be in accordance with the role of the IL-1 RI- 
mediated signal transduction pathway of the IL-1 effect in our
The finding of lower concentrations of ASAT and ALAT, 
markers of hepatocyte necrosis, in sera of IL-1-pretreated mice 
after infection is in accordance with our previous finding of 
IL-l-induced amelioration of liver histopathology (i.e., less 
glycogen depletion, fatty degeneration, and cell necrosis) (21. 
21a). Such protection is reminiscent of the IL-l-induced pro­
tection against acetaminophen-induced hepatotoxicity (15).
The exact mechanism of the IL-l-induced protection of liver 
hepatocytes and cells in other organs remains to be elucidated. 
An excess of cytokines and more distal inflammatory mediators 
such as leukotrienes, platelet-activating factor, nitric oxide, and 
superoxide radicals produced during lethal infection may be 
responsible for many pathologic phenomena. Recently, we 
were able to show that IL-1 pretreatm ent reduces cytokine 
production (25), and a role of this mechanism in the amelio­
rated pathologic changes is likely. On the o ther hand, antago­
nists of leukotrienes, prostaglandins, and platelet-activating 
factor were found not to affect IL-l-induced protection (23). In 
addition, IL-1 pre treatm ent might induce protection via desen­
sitization of the host to the overshoot of cytokines and inflam­
matory mediators (28). Such desensitization may occur either 
by induction of protective substances such as acute-phase pro­
teins, soluble cytokine receptors, or receptor antagonists (9, 22,
28), by downregulation of cytokine receptors, or by induction 
of intracellular protective proteins such as Mn-superoxide dis- 
mutase, heat shock proteins, or o ther protective proteins in 
target cells (8, 13).
In conclusion, the IL-1-induced protection against P. aerugi­
nosa infection in neutropenic mice seems to be mediated via 
IL-IRI. The nonapeptide fragment of rh IL - lp  is not protec­
tive. The IL-1-induced protection is associated with a signifi­
cant reduction in biochemical signs of hepatocyte damage, 
possibly reflecting the IL-l-induced reduction of cytokine over­
shoot during infection.
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